0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV-125.99%PremiumDec 20, 2024Expiry Date5.58Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Aquestive Therapeutics Stock Discussion
1 min ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film
Doesn't make sense to me?
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints
No comment yet